nContact, Inc. Announces First Patient Treated In The CONVERGE IDE Clinical Trial - The First Head-To-Head Superiority Study Comparing The Multidisciplinary Convergent Procedure To Endocardial Catheter Ablation In Persistent Atrial Fibrillation Patients

Published: Jan 09, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MORRISVILLE, N.C., Jan. 8, 2014 (GLOBE NEWSWIRE) -- nContact, Inc. today announced the first patient treated in the CONVERGE IDE Clinical Trial, a multicenter, prospective, randomized study evaluating patients with symptomatic persistent atrial fibrillation (AF). AF is the most common cardiac arrhythmia, estimated to affect 5.9 million people in the U.S., with a majority of patients falling into the difficult-to-treat persistent AF population. The CONVERGE Study is designed to investigate the treatment of persistent AF patients with the multidisciplinary Convergent Procedure, an epicardial-endocardial approach that utilizes the collaborative expertise and techniques of an electrophysiologist and cardiothoracic surgeon.

Help employers find you! Check out all the jobs and post your resume.

Back to news